Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[HTML][HTML] The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination
Background Sphingosine-one phosphate receptor (S1PR) modulation inhibits S1PR1-
mediated lymphocyte migration, lesion formation and positively-impacts on active multiple …
mediated lymphocyte migration, lesion formation and positively-impacts on active multiple …
Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies
TE Smith, M Madhavan, D Gratch, A Patel… - Multiple Sclerosis and …, 2022 - Elsevier
Background The risk of SARS-CoV-2 infection and severity with disease modifying therapies
(DMTs) in multiple sclerosis (MS) remains unclear, with some studies demonstrating …
(DMTs) in multiple sclerosis (MS) remains unclear, with some studies demonstrating …
[HTML][HTML] Patients with multiple sclerosis: COVID-19 related disease activity and hospitalisations based on a nationwide cohort study
ML Andersen, FD Zegers, LR Jølving… - Multiple Sclerosis and …, 2023 - Elsevier
Background It has not previously been clarified if COVID-19 triggers disease activity and
increases the risk of hospitalisation with COVID-19 in patients with multiple sclerosis. We …
increases the risk of hospitalisation with COVID-19 in patients with multiple sclerosis. We …
Humoral and cellular immune responses to SARS CoV-2 vaccination in people with multiple sclerosis and NMOSD patients receiving immunomodulatory treatments
H Bock, T Juretzek, R Handreka, J Ruhnau… - Multiple sclerosis and …, 2022 - Elsevier
Abstract Background Vaccination against SARS CoV-2 results in excellent personal
protection against a severe course of COVID19. In People with Multiple Sclerosis (PwMS) …
protection against a severe course of COVID19. In People with Multiple Sclerosis (PwMS) …
[HTML][HTML] Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: A prospective multicenter study
N Krajnc, H Hegen, G Traxler, F Leutmezer… - Multiple Sclerosis and …, 2022 - Elsevier
Background Third vaccination against SARS-CoV-2 is recommended for patients with
multiple sclerosis (pwMS), usually six months after the last vaccination. Methods In this …
multiple sclerosis (pwMS), usually six months after the last vaccination. Methods In this …
[HTML][HTML] Longitudinal epidemiology of multiple sclerosis in Townsville, Queensland, Australia, 2012-2022
S Simpson-Yap, D Maddox, J Reece… - Multiple sclerosis and …, 2023 - Elsevier
Abstract Background Townsville (population= 195,564, latitude= 19.3° S) is the largest city in
the Northern Queensland region of Australia, an area previously defined as a low/medium …
the Northern Queensland region of Australia, an area previously defined as a low/medium …
Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β
Background Interferon-β, a disease-modifying therapy (DMT) for MS, may be associated with
less severe COVID-19 in people with MS. Results Among 5,568 patients (83.4% confirmed …
less severe COVID-19 in people with MS. Results Among 5,568 patients (83.4% confirmed …